BRPI0516922A - composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica - Google Patents

composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica

Info

Publication number
BRPI0516922A
BRPI0516922A BRPI0516922-4A BRPI0516922A BRPI0516922A BR PI0516922 A BRPI0516922 A BR PI0516922A BR PI0516922 A BRPI0516922 A BR PI0516922A BR PI0516922 A BRPI0516922 A BR PI0516922A
Authority
BR
Brazil
Prior art keywords
ribavirin
ribavirin compound
compound
making
pharmaceutical composition
Prior art date
Application number
BRPI0516922-4A
Other languages
English (en)
Inventor
Travis Mickle
Sven Guenther
Original Assignee
New River Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New River Pharmaceuticals Inc filed Critical New River Pharmaceuticals Inc
Publication of BRPI0516922A publication Critical patent/BRPI0516922A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSTO DE RIBAVIRINA, MéTODO PARA FAZER UM COMPOSTO DE RIBAVIRINA, MéTODO PARA USAR UM COMPOSTO DE RIBAVIRINA E COMPOSIçãO FARMACêUTICA. A presente invenção refere-se a sistemas de liberação de ribavirina e mais especificamente a composições que compreendem amino ácidos, como amino ácidos ou peptídeos individuais, covalentemente ligados à ribavirina e a métodos para administrar composições de ribavirina conjugada.
BRPI0516922-4A 2004-11-02 2005-11-02 composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica BRPI0516922A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62385704P 2004-11-02 2004-11-02
PCT/US2005/039621 WO2006050421A1 (en) 2004-11-02 2005-11-02 Prodrugs of ribavirin with improved hepatic delivery

Publications (1)

Publication Number Publication Date
BRPI0516922A true BRPI0516922A (pt) 2008-09-23

Family

ID=36319525

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516922-4A BRPI0516922A (pt) 2004-11-02 2005-11-02 composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica

Country Status (10)

Country Link
US (1) US20080260691A1 (pt)
EP (1) EP1812039A1 (pt)
JP (1) JP2008522959A (pt)
KR (1) KR20070085544A (pt)
CN (1) CN101374539A (pt)
AU (1) AU2005302162A1 (pt)
BR (1) BRPI0516922A (pt)
CA (1) CA2586064A1 (pt)
IL (1) IL182941A0 (pt)
WO (1) WO2006050421A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504706A (ja) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー ＨＢＶ処置のためのＰＥＧ−ＩＦＮαおよびリバビリン
GB0614034D0 (en) * 2006-07-14 2006-08-23 Iqur Ltd Antiviral compounds
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
HUE032158T2 (en) 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
JP5656399B2 (ja) * 2008-12-26 2015-01-21 大塚製薬株式会社 医薬及び医薬製剤
JP6859559B2 (ja) * 2017-03-16 2021-04-14 二村　芳弘 抗アレルギー作用を呈するフェニルペプチド誘導体
CN111320662B (zh) * 2020-02-17 2022-11-25 南京医科大学 一类n-苄基取代的二脒那秦衍生物及其药物用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340696B1 (en) * 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment

Also Published As

Publication number Publication date
EP1812039A1 (en) 2007-08-01
CA2586064A1 (en) 2006-05-11
AU2005302162A1 (en) 2006-05-11
KR20070085544A (ko) 2007-08-27
JP2008522959A (ja) 2008-07-03
US20080260691A1 (en) 2008-10-23
IL182941A0 (en) 2007-09-20
CN101374539A (zh) 2009-02-25
WO2006050421A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
BRPI0516922A (pt) composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
BRPI0606687A2 (pt) composições nutracêuticas
HRP20080648A2 (en) Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
ATE534383T1 (de) Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
CL2011000314A1 (es) Composición farmacéutica estable que comprende linaclotida; método de preparación; y uso para preparar un medicamento útil para tratar un desorden gastrointestinal.
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
CR10124A (es) Formulaciones orales que comprenden tigeciclina
EP1881020A4 (en) POLYMERIC DERIVATIVE OF A METABOLIC ANTAGONIST OF CYTIDINE
BRPI0809366B8 (pt) polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
BRPI0513178A (pt) composições para distribuir fármacos altamente solúveis em água
MY169272A (en) Her2 antibody composition
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
NO20083973L (no) Farmasøytiske sammensetninger omfattende metylnaltrekson, kalsiumetylendiamintrieddiksyre og glycin.
BRPI0516577A (pt) agentes terapêuticos com toxicidade diminuìda
IL172783A0 (en) Rasgap derived peptide for selectively killing cancer cells
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
BRPI0819220A2 (pt) proteína neurturina ou fragmento da mesma, sua composição farmacêutica e uso
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SHIRE LLC (US)

Free format text: TRANSFERIDO POR FUSAO DE: NEW RIVER PHARMACEUTICALS INC.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]